Quality of life in mild to moderate acne: Relationship to clinical severity and factors influencing change with treatment

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 2, 2007, Pages 219-226

  Jones Caballero, M ^a   Chren, M M ^b   Soler, B ^c   Pedrosa, E ^d   Peñas, Pablo F ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CRO E C BIO   (Spain)

^d Yamanouchi Pharma   (Spain)

Author keywords

Acne; Quality of life; Questionnaire; Treatment outcome

Indexed keywords

ANTIBIOTIC AGENT; ERYTHROMYCIN; ZINC;

ACNE VULGARIS; ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL ASSESSMENT TOOL; COMEDO; CONTROLLED STUDY; CORRELATION ANALYSIS; DERMATITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ECZEMA; EMOTIONALITY; EPIDEMIOLOGICAL DATA; ERYTHEMA; FEMALE; FUNCTIONAL ASSESSMENT; GENDER BIAS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; OBSERVATIONAL STUDY; PAPULAR SKIN DISEASE; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUSTULE; QUALITY OF LIFE; SCORING SYSTEM; SENSITIVITY ANALYSIS; SKIN IRRITATION; SKIN PAIN; SKINDEX 29; SPAIN; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; XERODERMA;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ADULT; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; ERYTHROMYCIN; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; ZINC;

EID: 33846360019     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01907.x     Document Type: Article

References (27)

1. Kilkenny M, Merlin K, Plunkett A et al. The prevalence of common skin conditions in Australian school students: 3. acne vulgaris. Br J Dermatol 1998; 139: 840-845.
2. Kellett SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol 1999; 140: 273-282.
3. Cunliffe WJ. Acne and unemployment. Br J Dermatol 1986; 115: 386.
4. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139: 846-850.
5. Motley RJ, Finlay AY. How much disability is caused by acne? Clin Exp Dermatol 1989; 14: 194-198.
6. Motley RJ, Finlay AY. Practical use of a disability index in routine management of acne. Clin Exp Dermatol 1992; 17: 1-3.
7. Girman CJ, Hartmaier S, Thiboutot D et al. Evaluating health-related quality of life in patients with facial acne: Development of a self-administered questionnaire for clinical trials. Qual Life Res 1996; 5: 481-490.
8. Newton JN, Mallon E, Klassen A et al. The effectiveness of acne treatment: An assessment by patients of the outcome of therapy. Br J Dermatol 1997; 137: 563-567.
9. Layton AM, Seukeran D, Cunliffe WJ. Scarred for life? Dermatology 1997; 195: 15-21.
10. Gupta MA, Johnson AM, Gupta AK. The development of an Acne Quality of Life scale: Reliability, validity, and relation to subjective acne severity in mild to moderate acne vulgaris. Acta Derm Venereol 1998; 78: 451-456.
11. Grosshans E, Marks R, Mascaro JM et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol 1998; 139: 26-33.
12. Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998; 134: 454-458.
13. Mallon E, Newton JN, Klassen A et al. The quality of life in acne: A comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999; 140: 672-676.
14. Klassen AF, Newton JN, Mallon E. Measuring quality of life in people referred for specialist care of acne: Comparing generic and disease-specific measures. J Am Acad Dermatol 2000; 43: 229-233.
15. Simpson N. Effect of isotretinoin on the quality of life of patients with acne. Pharmacoeconomics 1994; 6: 108-113.
16. Mallon E, newton Jn, Klassen A et al. Standard patient assessed quality of life instruments can be used to measure the benefits of acne treatment. Br J Dermatol 1995; 133: 35.
17. Anderson R, Rajagopalan R. Responsiveness of the Dermatology-specific Quality of Life (DSQL) instrument to treatment for acne vulgaris in a placebo-controlled clinical trial. Qual Life Res 1998; 7: 723-734.
18. Ng CH, Tam MM, Celi E et al. Prospective study of depressive symptoms and quality of life in acne vulgaris patients treated with isotretinoin compared to antibiotic and topical therapy. Australas J Dermatol 2002; 43: 262-268.
19. Finlay AY. Quality of life assessments in dermatology. Semin Cutan Med Surg 1998; 17: 291-296.
20. Chren MM, Lasek RJ, Flocke SA et al. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 1433-1440.
21. Badía X, MascaróJM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol 1999; 141: 698-702.
22. Jones-Caballero M, Peñas PF, García-Díez A et al. The Spanish version of Skindex-29. Int J Dermatol 2000; 39: 907-912.
23. Jones-Caballero M, Peñas PF, Garcia-Diez A et al. La versión española de Skindex-29. Un instrumento de medida de la calidad de vida en pacientes con enfermedades cutáneas. Med Clin (Barc) 2002; 118: 5-9.
24. Witkowski JA, Parish LC. The assessment of acne: An evaluation of grading and lesion counting in the measurement of acne. Clin Dermatol 2004; 22: 394-397.
25. Shuster S, Fisher GH, Harris E et al. The effect of skin disease on self image. Br J Dermatol 1978; 99: 18-19.
26. Aktan S, Ozmen E, Sanli B. Anxiety, depression, and nature of acne vulgaris in adolescents. Int J Dermatol 2000; 39: 354-357.
27. Picardi A, Abeni D, Melchi CF et al. Psychiatric morbidity in dermatological outpatients: An issue to be recognized. Br J Dermatol 2000; 143: 983-991.